Abeona Therapeutics Announces License for Next Generation

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Abeona Therapeutics Announces License for Next Generation AAV Delivery Vector for Fanconi Anemia and Rare Blood Disease Platform

NEW YORK, NY --(Marketwired - October 06, 2015) - Abeona Therapeutics, Inc. ( NASDAQ : ABEO )

  • License enables lead CRISPR/Cas9 program for ABO-301 (AAV-FANCC) for Fanconi anemia and rare blood disorder platform
  • CRISPR/Cas9 mediated FANCC correction has demonstrated efficacy in cells from Fanconi anemia patients
  • Preclinical studies have demonstrated promising efficacy for treating Fanconi anemia disorder, a rare, fatal autosomal recessive disease

Abeona Therapeutics, Inc. ( NASDAQ : ABEO ), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced a license agreement with Stanford University for an AAV (adeno-associated virus) delivery vector for the treatment of Fanconi anemia (FA) and rare blood disease platform. This license augments a previously announced license agreement with the University of Minnesota for ABO-301 (AAV-FANCC) to treat patients with Fanconi anemia (FA) disorder and other rare blood diseases.

"Effective product development in gene therapy requires choosing the right delivery vehicle because each virus has a unique transduction profile that determines its ability to transfer genetic material from one organism to another," stated Steven Rouhandeh, Executive Chairman. "This licensing transaction complements our near-clinical stage programs in Sanfilippo syndromes (MPS IIIA and MPS IIIB), and juvenile Batten disease, as well as further expands our commitment to building a leadership position in the gene therapy space, with a focus on developing therapies for patients with rare diseases."

The major function of bone marrow is to produce new blood cells. In FA, a DNA mutation renders the FANCC gene nonfunctional. Loss of FANCC causes patient skeletal abnormalities and leads to bone marrow failure. Fanconi anemia patients also have much higher rates of hematological diseases, such as acute myeloid leukemia (AML) or tumors of the head, neck, skin, gastrointestinal system, or genital tract. The likelihood of developing one of these cancers in people with Fanconi anemia is between 10 and 30 percent. Aside from bone marrow transplantation (BMT) there are no specific treatments known that can halt or reverse the symptoms of FA. Repairing fibroblast cells in FA patients with a functional FANCC gene is the focus of our AAV-based gene therapy approach.

"The FANCC gene encodes a protein that functions as part of the pathway responsible for genome surveillance and repair of DNA damage. Hematopoietic progenitors are an ideal population for correction for therapeutic use. Our strategies encompass first and second generation therapies to correct hematopoietic cells," noted Tim Miller, Ph.D, President & CEO. "We are leveraging the unique capabilities of the CRISPR-Cas9 gene editing platform technology to build a robust product pipeline to address the unmet needs of patients that may have one of a variety of blood diseases, which include Beta-thalassemia, Fabry disease, as well as inherited forms of neutropenia, thrombocytopenia, and anemias."

About ABO-301 (AAV FANCC): ABO-301 is an AAV-based gene therapy which has shown promising preclinical efficacy in delivery of a normal copy of the defective gene to cells of the hematopoietic or blood system with the aim of reversing the effects of the genetic errors that cause Fanconi anemia.

The major function of bone marrow is to produce new blood cells. In FA, a DNA mutation renders the FANCC gene nonfunctional and increases errors in DNA repair. Loss of FANCC causes patient skeletal abnormalities and leads to bone marrow failure. Fanconi Anemia patients also have much higher rates of hematological diseases, such as acute myeloid leukemia (AML) or tumors of the head, neck, skin, gastrointestinal system, or genital tract. The likelihood of developing one of these cancers in people with Fanconi anemia is between 10 and 30 percent. Aside from bone marrow transplantation (BMT) there are no specific treatments known that can halt or reverse the symptoms of FA. Repairing fibroblast cells in FA patients with a functional FANCC gene is the focus of our AAV-based gene therapy approach.

Using a novel CRISPR (clustered, regularly interspaced short palindromic repeats)-Cas9 (CRISPR associated protein 9) system, researchers used a protein-RNA complex composed of an enzyme known as Cas9 bound to a guide RNA molecule that has been designed to recognize a particular DNA sequence. The RNA molecules guide the Cas9 complex to the location in the genome that requires repair. CRISPR-Cas9 uniquely enables surgically efficient knock-out, knock-down or selective editing of defective genes in the context of their natural promoters, unlocking the potential to treat both recessive and dominant forms of genetic diseases. Most importantly, this approach has the potential to allow safer, more precise gene modification for a wide range of rare blood diseases.

About Abeona: Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers and clinicians, anticipated to commence clinical trials in 2015. We are also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for the use of proceeds of the financing, our plans to begin enrolling patients in clinical trials for the treatment of Sanfilippo syndrome, development and internationalization of other clinical programs, management plans for the Company, the anticipated closing of the transaction, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Company and Media Contact: Andre'a Lucca Vice President of Communications Abeona Therapeutics, Inc. +1 (212)-786-6208 alucca@abeonatherapeutics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring CRH Stock Performance Over Five Years and Beyond

Updated Category News Views 152

Understanding CRH's Impressive Growth CRH has displayed a remarkable performance in the stock market over the last five years, outshining many of its competitors with a 10.67% annualized return. This impressive growth translates to an average annual return of 23.49% for investors. Currently, CRH boasts a market capitalization of approximately $73.09 billion, making it a...

Continue Reading
Coordinated Care's Health Tour Expands Access Across WA

Updated Category News Views 78

A Grassroots Push for Health Equity Coordinated Care, a subsidiary of Centene Corporation, is hitting the road in Washington state. This isn't about just another healthcare campaign—you’ve got two vans, 'SeeMore' and 'Flossy', bringing essential vision and dental screenings right up to the folks who need them most. Taking Healthcare Directly to Communities Let's be...

Continue Reading
Italy's Antitrust Agency Investigates Snam-Edison Deal

Updated Category News Views 229

Investigation into the Snam and Edison Gas Storage Deal Italy's antitrust agency has recently initiated an investigation concerning the transaction between Snam and Edison involving Edison's gas storage unit. This move reflects the agency's commitment to maintaining healthy competition within the energy sector. Concerns Over Market Competition The Antitrust Authority,...

Continue Reading
Truist Financial Corporation's Quarterly Performance Insights

Updated Category News Views 240

Truist Financial's Results and Earnings Overview Truist Financial Corporation (TFC) announced its latest quarterly results, showcasing a robust financial performance that illustrates the company’s strategic focus on growth and stability. This release reflects the commitment of Truist to enhance the lives of its clients and communities by providing comprehensive...

Continue Reading
Investigation Into Possible Securities Fraud at UnitedHealth Group

Updated Category News Views 350

UnitedHealth Group Under Scrutiny for Securities Claims Ademi & Fruchter LLP has launched an investigation into potential securities fraud claims against UnitedHealth Group Incorporated (NYSE: UNH). This inquiry arises following inaccurate statements made by the company regarding its operational performance and future outlook. Investors and analysts alike express serious...

Continue Reading